Overview
Neurological recovery protocols typically run 40–60 sessions at 2.0 ATA, five days a week. Some protocols introduce intermittent higher-pressure sessions (2.2 ATA) or add "boost" phases based on clinical response. Imaging (SPECT or perfusion MRI) is sometimes used to track perfusion and neuroplasticity. Response varies — approximately 60–80% of TBI participants in the Hadanny trials showed cognitive gains.
Neurological recovery HBOT is the fastest-growing research-stage application of hyperbaric medicine. The Efrati Lab framework — 40–60 sessions at 2.0 ATA — has been applied across TBI, stroke, long COVID, fibromyalgia, PTSD, concussion, and age-related cognitive decline with consistent signal across trials.
The protocol combines daily attendance with pre- and post-course objective assessment. Standard pre-treatment evaluation includes neurocognitive batteries (ANAM, CNS Vital Signs, domain-specific tests), quality-of-life questionnaires, and often imaging (SPECT or perfusion MRI). Interim assessment at session 20 helps identify responders early. Post-course assessment at 1–3 months captures the delayed neuroplastic improvement that often continues after treatment completion.
Variants exist. Some protocols use 60 sessions rather than 40 for severe cases or longevity applications. Some incorporate "boost" sessions at 2.2 ATA for a subset of the course. Some add specific adjuncts (cognitive rehabilitation, physical therapy, graded exercise) during the course. The core framework remains 40 sessions at 2.0 ATA.
Protocol Parameters
| Pressure | 2.0 ATA (occasional 2.2 ATA boost) |
|---|---|
| Session length | 90 minutes |
| Frequency | 5 days/week |
| Typical course | 40–60 sessions |
Indications
- TBI (mild-moderate)
- Ischaemic stroke recovery
- Long COVID / brain fog
- Post-concussion syndrome
- PTSD (research)
- Age-related cognitive decline (research)
Neurological recovery HBOT is off-label in most jurisdictions. The Efrati Lab 2.0 ATA / 40-session framework is the most-studied; variants (60 sessions, higher-pressure boosts) are used for specific indications or severity levels.
Evidence Base
Multiple Efrati-lab RCTs; emerging long-COVID literature post-2022.
Neurological recovery HBOT is UHMS Tier 2 (research-stage). The evidence base is strongest for TBI, stroke, long COVID, and fibromyalgia at 2.0 ATA over 40–60 sessions. Replication across multiple centres and larger trials is pending for most indications.
Cautions & Notes
- Off-label in most jurisdictions
- Response variability — plateau assessment at session 20 is advisable
- Cash-pay cost of $6,000–$18,000 for a full course in US private clinics
- Standard HBOT contraindications apply
Practical Considerations
Neurological recovery HBOT courses require daily attendance over 8–12 weeks. Response is often progressive and may continue to improve for 1–3 months after course completion. Patients should maintain standard rehabilitation (physical, occupational, speech therapy as applicable) during the course.
Frequently Asked Questions
Who is a good candidate for neurological HBOT?
Patients with persistent neurological symptoms (3+ months) from TBI, stroke, long COVID, or similar conditions who have plateaued on standard rehabilitation. Response is more likely in motivated patients who can commit to the full course.
What if I do not respond?
Approximately 20–40% of patients in neurological HBOT trials do not show significant benefit. If the interim assessment at session 20 shows no response, the hyperbaric team will discuss whether to continue, modify, or discontinue the course.
Does neurological HBOT work for Alzheimer's or Parkinson's?
Early-stage research only. These conditions are not yet established HBOT indications; evidence base is thinner than TBI, stroke, or long COVID. Clinical trials are underway.
Research disclaimer: This protocol summary is for educational purposes only. HBOT is a regulated medical treatment that must be administered under appropriate professional supervision. Always consult a qualified physician before initiating hyperbaric therapy.